SCHEMBL4865713

SCHEMBL4865713

CC(=O)Nc1ccccc1Oc1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.54
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 1/20 0.50
BRD4 O60885 1/20 0.50
ALDH1A1 P00352 2/20 0.49
ATM Q13315 1/20 0.49
GAA P10253 3/20 0.49
PKM P14618 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PYGL P06737 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30327328 0.87 ADRA2C (0.64) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL2342698 0.87 ADRA2C (0.64) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL16316797 0.84 L3MBTL1 (0.56) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL10822262 0.83 BRD4 (0.62) LMNASMN1; SMN2L3MBTL1POLBMAPT
SCHEMBL30892502 0.83 BRD4 (0.62) LMNASMN1; SMN2L3MBTL1POLBMAPT
SCHEMBL29954205 0.82 HSD17B10 (0.50) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL7010626 0.81 L3MBTL1 (0.50) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL10946928 0.81 BRD4 (0.53) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
Hydrochloric Acid SCHEMBL11330417 0.81 NPSR1 (0.48) ADRA2CLMNASMN1; SMN2L3MBTL1POLB
SCHEMBL12952688 0.81 P2RY1 (0.58) ADRA2CLMNASMN1; SMN2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384963-B2 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase GLAXO GROUP LIMITED (GB) 2008-06-10 US disclosed
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435949-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032986-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
EP-0271656-B1 REACTIVE AMINO ALKOXY-TRIPHENE DIOXAZINE DYES BAYER AG (DE) 1990-08-01 EP disclosed
US-4874857-A FIBER-REACTIVE DYES BAYER AKTIENGESELLSCHAFT (DE) 1989-10-17 US disclosed
EP-0271656-A1 Reactive amino alkoxy-triphene dioxazine dyes BAYER AG (DE) 1988-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors MAPK1, MAPK3, MAPK6 ADRA2C 292/4885LMNA 3396/4885SMN1; SMN2 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.